KYORIN Pharmaceutical Co., Ltd. Logo

KYORIN Pharmaceutical Co., Ltd.

Researches, develops, and sells a portfolio of ethical, generic, and OTC medicines.

4569 | T

Overview

Corporate Details

ISIN(s):
JP3247090008
LEI:
Country:
Japan
Address:
千代田区大手町一丁目3番7号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

KYORIN Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and commercialization of medicines. The company's business focuses on several key areas, including the creation of innovative new ethical drugs through its own drug discovery and in-licensing activities. Its portfolio also encompasses generic drugs and over-the-counter (OTC) products, such as the COOL ONE series. The company aims to contribute to public health by developing high-value treatments that meet medical needs. In April 2023, the current entity was formed when KYORIN Holdings, Inc. merged with its wholly-owned subsidiary, KYORIN Pharmaceutical Co., Ltd., and adopted the subsidiary's name.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 07:42
Interim Report
確認書
Japanese 8.9 KB
2025-11-13 07:36
Interim Report
半期報告書-第68期(2025/04/01-2025/09/30)
Japanese 220.9 KB
2025-06-26 07:25
Post-Annual General Meeting Information
臨時報告書
Japanese 23.5 KB
2025-06-19 08:55
Governance Information
内部統制報告書-第67期(2024/04/01-2025/03/31)
Japanese 27.1 KB
2025-06-19 08:53
Registration Form
確認書
Japanese 8.9 KB
2025-06-19 08:50
Registration Form
有価証券報告書-第67期(2024/04/01-2025/03/31)
Japanese 1.4 MB
2024-11-13 07:27
Interim Report
確認書
Japanese 8.9 KB
2024-11-13 07:24
Interim Report
半期報告書-第67期(2024/04/01-2025/03/31)
Japanese 216.2 KB
2024-06-28 08:30
Post-Annual General Meeting Information
臨時報告書
Japanese 23.5 KB
2024-06-24 08:53
Governance Information
内部統制報告書-第66期(2023/04/01-2024/03/31)
Japanese 24.3 KB
2024-06-24 08:51
Registration Form
確認書
Japanese 8.9 KB
2024-06-24 08:47
Registration Form
有価証券報告書-第66期(2023/04/01-2024/03/31)
Japanese 1.3 MB
2024-02-14 07:07
Quarterly Report
確認書
Japanese 8.9 KB
2024-02-14 07:05
Quarterly Report
四半期報告書-第66期第3四半期(2023/10/01-2023/12/31)
Japanese 190.9 KB
2023-11-14 07:36
Report Publication Announcement
確認書
Japanese 8.2 KB

Automate Your Workflow. Get a real-time feed of all KYORIN Pharmaceutical Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KYORIN Pharmaceutical Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KYORIN Pharmaceutical Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BOIRON Logo
Global manufacturer of homeopathic medicines for pain relief and flu-like symptoms, sold worldwide.
France
BOI
Bon Natural Life Ltd Logo
Bio-manufactures natural plant ingredients for fragrances, supplements, and immunity solutions.
United States of America
BON
Bosnalijek d.d. Sarajevo Logo
Global manufacturer of drugs for digestive, metabolic, and cardiovascular health.
Bosnia and Herzegovina
BSNL
Boundless Bio, Inc. Logo
Developing ecDNA-directed therapies for intractable oncogene amplified cancers.
United States of America
BOLD
BridgeBio Oncology Therapeutics, Inc. Logo
Clinical-stage biopharma creating small molecule drugs for RAS-dependent cancers.
United States of America
BBOT
BridgeBio Pharma, Inc. Logo
Develops transformative medicines for genetic diseases and genetically driven cancers.
United States of America
BBIO
BRIGHT MINDS BIOSCIENCES INC. Logo
Developing next-gen serotonergic drugs for neurological and psychiatric disorders like epilepsy.
United States of America
DRUG
BRISTOL MYERS SQUIBB CO Logo
Develops innovative medicines for oncology, immunology, and cardiovascular diseases.
United States of America
BMY
R&D pharma firm developing drugs for CNS disorders, oncology, and metabolic diseases.
South Korea
003000
Burning Rock Biotech Ltd Logo
Offers NGS-based diagnostics for precision oncology, from detection to clinical trial support.
United States of America
BNR

Talk to a Data Expert

Have a question? We'll get back to you promptly.